These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31436584)

  • 1. Biomarkers in systemic sclerosis.
    Skaug B; Assassi S
    Curr Opin Rheumatol; 2019 Nov; 31(6):595-602. PubMed ID: 31436584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of skin and lung fibrosis in systemic sclerosis.
    Martinović Kaliterna D; Petrić M
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1215-1223. PubMed ID: 31539483
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging biomarkers in systemic sclerosis.
    Manetti M
    Curr Opin Rheumatol; 2016 Nov; 28(6):606-12. PubMed ID: 27380110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS.
    Pawlik KK; Bohdziewicz A; Chrabąszcz M; Stochmal A; Sikora M; Alda-Malicka R; Czuwara J; Rudnicka L
    Wiad Lek; 2020; 73(10):2300-2305. PubMed ID: 33310967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in systemic sclerosis: Their potential to predict clinical courses.
    Hasegawa M
    J Dermatol; 2016 Jan; 43(1):29-38. PubMed ID: 26782004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.
    Castelino FV; Varga J
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1077-90. PubMed ID: 24168414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
    Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.
    Utsunomiya A; Oyama N; Hasegawa M
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33105647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating biomarkers of systemic sclerosis - interstitial lung disease.
    Hoffmann-Vold AM; Fretheim H; Meier C; Maurer B
    J Scleroderma Relat Disord; 2020 Mar; 5(2 Suppl):41-47. PubMed ID: 35382223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.
    Martyanov V; Whitfield ML
    Curr Opin Rheumatol; 2016 Jan; 28(1):83-8. PubMed ID: 26555452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
    Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
    Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scleroderma Skin: How Is Treatment Best Guided by Data and Implemented in Clinical Practice?
    Vonk MC; Assassi S; Hoffmann-Vold AM
    Rheum Dis Clin North Am; 2023 May; 49(2):249-262. PubMed ID: 37028833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of biomarkers to clinical trials in systemic sclerosis.
    Lafyatis R
    Curr Rheumatol Rep; 2012 Feb; 14(1):47-55. PubMed ID: 22052444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review.
    Paxton D; Pauling JD
    Semin Arthritis Rheum; 2018 Dec; 48(3):482-494. PubMed ID: 29602558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.
    Bonhomme O; André B; Gester F; de Seny D; Moermans C; Struman I; Louis R; Malaise M; Guiot J
    Rheumatology (Oxford); 2019 Sep; 58(9):1534-1546. PubMed ID: 31292645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
    J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.